Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Parnell (OTC: PARNF) is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal and human health solutions. Parnell is a technology and clinical science leader in dairy reproduction, marketing its proprietary brands estroPLAN and GONAbreed... Parnell (OTC: PARNF) is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal and human health solutions. Parnell is a technology and clinical science leader in dairy reproduction, marketing its proprietary brands estroPLAN and GONAbreed via its dedicated sales force and digital technology mySYNCH in the USA and Australia-New Zealand, and via distributors in other markets. Parnell has a rapidly growing contract manufacturing business supplying industry majors with specialized sterile injectable products. In companion animal, Parnell manufactures and markets its proprietary canine osteoarthritis brands Zydax and Glyde. For more information on the company and its products, please visit www.parnell.com. Mehr anzeigen
OVERLAND PARK, Kan., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial-stage pharmaceutical company focused on developing...
OVERLAND PARK, Kan., Dec. 09, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial-stage pharmaceutical company focused on developing...
OVERLAND PARK, Kan., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and...
OVERLAND PARK, Kansas, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial-stage pharmaceutical company focused on developing...
OVERLAND PARK, Kan., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd. (Nasdaq:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and...
OVERLAND PARK, Kan., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial-stage pharmaceutical company focused on developing...
OVERLAND PARK, Kan., July 26, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd. (Nasdaq:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and...
OVERLAND PARK, Kan., May 31, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial-stage pharmaceutical company focused on developing...
OVERLAND PARK, Kan., May 12, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial-stage pharmaceutical company focused on developing...
Parnell continues to grow rapidly with revenue increasing 43% for the three months ended March 31, 2016OVERLAND PARK, Kan., April 22, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.268 | -76.5714285714 | 0.35 | 0.35 | 0.082 | 29359 | 0.10951122 | CS |
| 4 | 0.032 | 64 | 0.05 | 0.35 | 0.05 | 34392 | 0.06693432 | CS |
| 12 | 0.032 | 64 | 0.05 | 0.35 | 0.05 | 34392 | 0.06693432 | CS |
| 26 | 0.0819 | 81900 | 0.0001 | 0.35 | 1.0E-6 | 21135 | 0.06535084 | CS |
| 52 | 0.081999 | 8199900 | 1.0E-6 | 0.35 | 1.0E-6 | 13691 | 0.06305566 | CS |
| 156 | 0.0818 | 40900 | 0.0002 | 0.35 | 1.0E-6 | 12880 | 0.01724424 | CS |
| 260 | -0.038 | -31.6666666667 | 0.12 | 0.89 | 1.0E-6 | 12687 | 0.21105413 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
